Umbilical cord blood (UCB) has emerged as a safe and effective hematopoietic cell (HC) source for adult acute leukemia patients who lack an HLA-matched donor. 1 While UCB transplants offer advantages compared with other allogeneic HC sources, their hematopoietic engraftment and immune reconstitution are delayed and limited by the number of HCs contained in the UCB unit together with donor-recipient HLA disparities. 2 A dual transplant strategy combining UCB plus third-party donor (TPD) HC (UCB-TPD) pioneered at Hospital Puerta de Hierro in Madrid has been shown to improve early outcomes after UCB transplantation by hastening hematopoietic recovery. 3 Here, we present an independent series of 13 consecutive high-risk myelodysplastic syndrome (MDS)/AML and ALL patients, median age 45 years (20-64) and weight 71 Kg (56-104), who received a myeloablative UCB-TPD dual transplant in our center from February 2009 to January 2013. Patients lacked a matched related or unrelated donor, were in advanced stage and heavily pretreated: seven refractory to X1 line of chemotherapy, three relapsed after a previous HC transplant, and two had active AML (9 and 22% blasts) prior to UCB-TPD transplant (Table 1) . Our non-TBI chemotherapy-based myeloablative 4 conditioning and GVHD prophylaxis regimen included BU (12 mg/kg), CY (100 mg/kg), fludarabine (120 mg/m 2 ), thymoglobulin (4 mg/kg), CsA and a short course of methylprednisolone. Patients received UCB units with 1-3 out of 6 HLA mismatches (A, B antigenic; DR allelic), a median post-thawing total nucleated cell count of 2.62 Â 10 7 /kg (1.39-5.8) and CD34 þ cell count of 0.98 Â 10 5 /kg (0.35-2.26), 5 followed by a median 4.96 Â 10 6 /kg miltenyi-purified TPD CD34 þ cells (3.62-11.90) with o1 Â 10 4 /kg CD3 þ cells (Table 2) . TPD were haploidentical relatives in all cases but one, patient no. 9, whose TPD was a fully mismatched brother. G-CSF (30MU) was administered from day þ 1 until sustained neutrophil engraftment 41 Â 10 9 /L. All patients engrafted neutrophils 40.5 Â 10 9 /L and platelets 420 Â 10 9 /L by median days þ 12 (range, 10-17) and þ 23 (range, 12-105), respectively. Twelve cases (92%) achieved fulldonor chimerism as early as 2 weeks after UCB-TPD transplant. Donor chimerism and engraftment were initially derived from the TPD in all cases, and shifted rapidly to UCB in all evaluable patients but one, case no. 10, whose post-thawing UCB viability and cell counts (Table 2) were low, failing to engraft the CBU and remaining in CR and sustained haploidentical donor chimerism until his most recent follow-up, 15 months after transplant.
Antiviral prophylaxis with acyclovir and prophylaxis against pneumocystis jirovecii with pentamidine or trimethoprim-sulfamethoxazole were administered for 1 year. Antifungal prophylaxis with posaconazole was administered for 100 days after transplant, or longer as required for GVHD. Patients received no formal antibacterial prophylaxis. However, two cases of grade IV hemorrhagic cystitis (no. 6 and no. 7) prompted us to routinely introduce post-transplant ciprofloxacin prophylaxis against polyomavirus, 6 during 60 days regardless of IV broad-spectrum antibiotics from patient no. 8 onwards, with only one additional case of polyomavirus hemorrhagic cystitis (grade II) since. There were three episodes of bacteremia (Streptococcus faecium in no. 5, Escherichia coli in no. 10 and Streptococcus mitis in no. 12) and one episode of isolated urinary tract infection (Escherichia coli in no. 2) during the neutropenic phase, but most opportunistic infections occurred after granulocyte engraftment. Seven patients (54%) presented CMV reactivation, two of them (no. 4 and no. 8) in the context of high-dose corticosteroids for grade II acute cutaneous GHVD. There was one case of unknown-origin communityacquired pneumonia and one case of H1N1 influenza, three and five months after transplantation, respectively. Patient no. 10 with full haploidentical chimera after UCB graft failure developed no opportunistic infections. Three patients (23%) had non-relapse deaths 6-16 months after transplantation from infectious complications (one gram-negative bacteria cellulitis and sepsis, one septic shock of unknown origin and one CMV pneumonitis). Four patients (30.7%) developed grade II and one (7.7%) grade III acute cutaneous GVHD, the latter followed by a subsequent quiescent chronic GVHD five months after transplantation (Table 1 ). Both patients with active AML achieved a CR after UCB-TPD transplant and remained in CR at their last follow-ups, 16 and 43 months post transplant. Despite the high-risk of this cohort, only one patient (no. 7), who arrived to transplant in first CR having required one course of induction and two courses of salvage chemotherapy, relapsed after transplant (7.7%). Sixty-nine percent of these high-risk patients (9 out of 13) remain alive and in CR at a median follow-up of 22 (4-51) months after UCB-TPD transplant.
The UCB-TPD dual strategy appears to improve early outcomes by reproducibly hastening hematopoietic recovery after UCB transplantation in a variety of settings. Ferná ndez et al. 3 and Kwon et al. 7 have shown similar outcomes when comparing the UCB-TPD dual strategy to myeloablative allogeneic transplantation from HLA-matched related and unrelated donors, respectively. Liu et al. have successfully applied this strategy to a somewhat older cohort of patients using a reduced intensity conditioning regimen, which despite good early outcomes, led to prolonged mixed chimerism and persistent recipient hematopoiesis that may raise potential concerns regarding the risk of disease relapse at a longer follow-up than their reported 11 months. 8 Moreover, two additional groups have reported the use of this strategy in young patients with severe aplastic anemia and metabolic disorders. 9, 10 Our independent single-center series reproduces the favorable results of the UCB-TPD dual strategy and shows that prompt engraftment and full-donor chimerism can be rapidly achieved following a non-TBI chemotherapy-based myeloablative conditioning of reduced extra-hematological After refractoriness to a 1st FLAG-Ida (22% blasts), the UCB-TPD dual transplant was performed in aplasia, 2 weeks after a 2nd FLAG-Ida.
letter to the Editor toxicity, while maintaining low incidences of relapse, non-relapse mortality and GVHD in a cohort of high-risk acute leukemia patients, 38.5% of whom were 50 years of age or older. They also suggest that shorter time to engraftment may be a main driver of improved outcome in UCB transplant, and that the UCB-TPD strategy can reproducibly achieve this goal in multiple clinical settings. Future larger studies are warranted to help the transplant community to tailor this promising approach to patient and disease characteristics in order to improve the outcomes even further. letter to the Editor
